What is the recommended management for adult anxiety, including non‑pharmacologic and pharmacologic therapies?

Management of Adult Anxiety

For adult anxiety disorders, initiate treatment with either SSRIs (selective serotonin reuptake inhibitors) or cognitive behavioral therapy (CBT) as first-line monotherapy, with the choice determined by symptom severity, patient preference, and resource availability. 1

Pharmacological Management

First-Line Medications

SSRIs are the recommended first-line pharmacotherapy for anxiety disorders (GRADE 2C - weak recommendation, low certainty evidence). 1 Specific agents include:

• Fluvoxamine
• Paroxetine
• Escitalopram

Venlafaxine (SNRI) is also suggested as first-line therapy (GRADE 2C - weak recommendation, low certainty evidence). 1

These medications are well-tolerated without considerable long-term adverse effects and should be the primary pharmacological choice. 2

Duration and Monitoring

• Continue medications for 6-12 months after achieving remission to prevent relapse. 3, 4
• The main pharmacological decision is between daily medication versus short-acting as-needed medication for intermittent symptoms.

Medications to Avoid

Benzodiazepines are NOT recommended due to risk of adverse effects, particularly with long-term use, despite their common use in clinical practice. 2, 3 This is a critical pitfall to avoid—while benzodiazepines may provide rapid symptom relief, their long-term risks outweigh benefits.

Non-Pharmacological Management

Cognitive Behavioral Therapy (Primary Recommendation)

CBT specifically developed for anxiety disorders is the recommended psychotherapy (weak recommendation, low certainty evidence). 1, 5

• Individual CBT sessions by a skilled therapist are prioritized over group therapy due to superior clinical and health-economic effectiveness. 1
• CBT models include the Clark and Wells model or Heimberg model for social anxiety disorder.
• Brief CBT delivered in primary care by embedded behavioral health clinicians is effective. 2

Alternative Non-Pharmacological Options

If patients decline face-to-face CBT:

• Self-help with support based on CBT principles is suggested as an alternative. 1
• Digital interventions and online platforms show promise for mild-to-moderate anxiety. 6

Other evidence-supported approaches include:

• Psychodynamic therapy (when CBT is ineffective, unavailable, or patient-preferred after informed discussion). 3
• Virtual reality exposure therapy
• Internet-based interventions 3

Treatment Algorithm

For Subthreshold or Adjustment-Related Anxiety

Start with self-help and behavioral treatment before escalating to formal therapy or medications. 2

For Diagnosed Anxiety Disorders

1. Initial Treatment Selection:

   • Offer either SSRI/SNRI OR CBT as monotherapy
   • Consider presentation severity, patient preference, treatment history, and potential adverse effects
   • Engage in shared decision-making 2

2. If Initial Treatment Fails:

   • Switch to the alternative modality (if started on medication, switch to CBT; if started on CBT, switch to medication)
   • OR combine both approaches 3

3. For Treatment-Resistant Cases:

   • Consider alternative pharmacological strategies (pregabalin, tricyclic antidepressants, buspirone, moclobemide) 4
   • Implement Collaborative Care Management model involving primary care clinicians, consulting psychiatrists, and care managers 2

Important Note on Combination Therapy

There is NO formal recommendation for routine combined pharmacotherapy and psychotherapy based on current evidence. 1 However, when monotherapy fails, combination becomes a reasonable next step. 3

Clinical Considerations

Assessment Requirements

• Use patient-reported symptom measures
• Conduct clinical interview focusing on fear/anxiety triggers, avoidance behaviors, duration (typically ≥6 months), and functional impairment
• Perform physical examination to rule out medical causes
• Order appropriate laboratory tests to exclude physiological causes 2

Screening

Screen all primary care patients younger than 65 years for anxiety disorders, as anxiety is frequently underdetected and undertreated in primary care settings. 2, 4

Treatment Efficacy Monitoring

Monitor patient progress systematically, particularly when using the Collaborative Care Management model, which has demonstrated superior outcomes compared to usual primary care. 2

The evidence base for anxiety treatment, while showing consistent direction toward SSRIs/SNRIs and CBT, carries predominantly low-to-moderate certainty. 1 This reflects the complexity of anxiety disorders rather than ineffectiveness of treatments—both pharmacological and psychological interventions demonstrate meaningful clinical benefit in reducing morbidity and improving quality of life.